Cutting-Edge Research to Foster 8 Billion Smiles ― Dentistry for a New Era ― - The 6th International Dental Symposium

JP
EN

Session

Moderator

Japan

Professor, Division of Molecular and Regenerative Prosthodontics, Tohoku University Graduate School of Dentistry
Joint Research Department of Next-Generation Dental Material Engineering, Tohoku University Graduate School of Dentistry 東北大学大学院歯学研究科
分子・再生歯科補綴学分野教授
東北大学大学院歯学研究科
次世代歯科材料工学共同研究講座

Dr. DT DH

10/ 3(Sat)

10:30 - 12:00

4F〜6F ホール C

Session 59

Cutting-Edge Research to Foster 8 Billion Smiles
― Dentistry for a New Era ―

80億の笑顔を創る最先端研究
～日本発・世界初、時代が変わる～

Two researchers dedicated to ‘creating smiles for 8 billion people’ will share Japans cutting-edge research transforming the world.
Prof. Tsukasaki unravels the “mysterious power” of inflammation that destroys bone while simultaneously promoting regeneration. His discoveries, including the periosteums defense mechanisms against cancer invasion, are continuously reported, rewriting the conventional wisdom of the bone world.
Meanwhile, Dr. Takahashi is bringing revolutionary treatment closer to reality—where “lost teeth grow back.”
A 90-minute session that will change the norms of dental care. This message is for all dental professionals!

Japan

Prof. Masayuki
Tsukasaki 塚崎
雅之先生

Professor, Department of Biochemistry, School of Dentistry, Showa Medical University 昭和医科大学歯学部口腔生化学講座教授

Lecturer

New insights into inflammatory bone destruction and bone formation

炎症性骨破壊・骨形成機構の最前線

Effects of inflammation on bone
Pathogenesis of oral cancer
Molecular mechanisms of vascular calcification

炎症の骨への影響
口腔がんの病態
血管石灰化のメカニズム

Inflammation exerts diverse effects on the skeleton. In pathological conditions such as periodontal disease, rheumatoid arthritis, and cancer-associated bone metastasis or invasion, osteoclast-mediated bone destruction represents a major clinical problem. Inflammation can also promote ectopic osteogenesis under certain conditions; however, the mechanisms underlying inflammatory bone formation remain largely unclear. In this symposium, I will discuss recent advances in our understanding of the molecular mechanisms governing pathological bone metabolism.

Japan

Dr. Katsu
Takahashi 髙橋
克先生

CTO, Toregem BioPharma Co., Ltd.
Chief of Oral and Maxillofacial Surgery, Medical Research Institute KITANO HOSPITAL, PIIF Tazuke-Kofukai トレジェムバイオファーマ株式会社取締役CTO
（公財）田附興風会医学研究所北野病院
歯科口腔外科主任部長

Lecturer

Development of a new antibody drug to treat congenital tooth agenesis

先天性無歯症患者の欠如歯を再生する新規抗体医薬品の開発

Classification and Pathogenesis of Congenital Tooth Agnesis
History of Research and Development for Congenital Tooth Agenesis
Current Status of Clinical Development for Congenital Tooth Agenesis
Recruitment of Subjects for Clinical Trials of Congenital Tooth Agenesis
Future Prospects for Research and Development of Congenital Tooth Agenesis

先天性無歯症の分類、発症メカニズム
先天性無歯症治療薬の研究開発の経緯
先天性無歯症治療薬の臨床開発の現況
先天性無歯症治療薬の臨床治験に向けた対象患者のリクルート
先天性無歯症治療薬の研究開発の展望

Congenital anodontia is a condition characterized by the absence of teeth from birth. Mouse anti-USAG-1 antibodies demonstrated the ability to restore congenitally missing teeth with a single administration in congenital anodontia model mice and Beagle dogs. Based on in vitro/in vivo activity and other factors, the humanized anti-USAG-1 antibody TRG035 was selected as the final development candidate. With support from numerous researchers, companies, and the government, the world's first Phase I clinical trial of TRG035 (commonly known as the “tooth-growing drug”), a molecularly targeted drug to regenerate missing teeth in congenital anodontia patients, commenced in late October 2024 at Kyoto University Hospital and Kitano Hospital. The trial was completed in September 2025.

Registration